Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy.
作者信息
Su Feng, Ioannou George N
机构信息
Division of Gastroenterology University of Washington Seattle WA.
Health Services Research and Development Veterans Affairs Puget Sound Healthcare System Seattle WA.
出版信息
Clin Liver Dis (Hoboken). 2019 Feb 21;13(1):6-12. doi: 10.1002/cld.781. eCollection 2019 Jan.
Abstract
摘要
相似文献
1
Hepatocellular Carcinoma Risk After Direct-Acting Antiviral Therapy.直接抗病毒治疗后肝细胞癌的风险
Clin Liver Dis (Hoboken). 2019 Feb 21;13(1):6-12. doi: 10.1002/cld.781. eCollection 2019 Jan.
2
Inflammatory patterns in plasma associate with hepatocellular carcinoma development in cured hepatitis C cirrhotic patients.血浆中的炎症模式与已治愈的丙型肝炎肝硬化患者肝癌的发展相关。
United European Gastroenterol J. 2021 May;9(4):486-496. doi: 10.1177/2050640620976991. Epub 2021 Feb 18.
3
Direct-acting antiviral therapy decreases hepatocellular carcinoma recurrence rate in cirrhotic patients with chronic hepatitis C.直接作用抗病毒疗法可降低丙型肝炎肝硬化患者肝癌复发率。
Liver Int. 2017 Aug;37(8):1122-1127. doi: 10.1111/liv.13456. Epub 2017 May 25.
4
Early development of de novo hepatocellular carcinoma after direct-acting agent therapy: Comparison with pegylated interferon-based therapy in chronic hepatitis C patients.直接作用抗病毒药物治疗后新发肝细胞癌的早期发生：与慢性丙型肝炎患者聚乙二醇干扰素治疗的比较
J Viral Hepat. 2018 Oct;25(10):1189-1196. doi: 10.1111/jvh.12918. Epub 2018 May 17.
5
Hepatitis C virus relapse after successful treatment with direct-acting antivirals, followed by sarcomatous changes in hepatocellular carcinoma: a case report.直接作用抗病毒药物治疗后成功的丙型肝炎病毒复发，随后发生肝细胞癌肉瘤样改变：一例报告。
J Med Case Rep. 2020 May 27;14(1):62. doi: 10.1186/s13256-020-02392-y.
6
Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.直接作用抗病毒治疗后慢性丙型肝炎患者的临床结局：一项前瞻性队列研究。
Lancet. 2019 Apr 6;393(10179):1453-1464. doi: 10.1016/S0140-6736(18)32111-1. Epub 2019 Feb 11.
7
Serum GP88 as a predictive biomarker for hepatocellular carcinoma in patients with viral hepatitis C after direct-acting antiviral agents.血清GP88作为丙型病毒性肝炎患者接受直接抗病毒药物治疗后肝细胞癌的预测生物标志物。
Ann Clin Biochem. 2021 Nov;58(6):605-613. doi: 10.1177/00045632211036723. Epub 2021 Aug 11.
8
Newly diagnosed hepatocellular carcinoma in patients with advanced hepatitis C treated with DAAs: A prospective population study.接受 DAA 治疗的晚期丙型肝炎患者新诊断的肝细胞癌：一项前瞻性人群研究。
J Hepatol. 2018 Aug;69(2):345-352. doi: 10.1016/j.jhep.2018.03.009. Epub 2018 Mar 16.
9
Time association between hepatitis C therapy and hepatocellular carcinoma emergence in cirrhosis: Relevance of non-characterized nodules.丙型肝炎治疗与肝硬化中肝细胞癌发生的时间关联：非特征性结节的相关性。
J Hepatol. 2019 May;70(5):874-884. doi: 10.1016/j.jhep.2019.01.005. Epub 2019 Jan 24.
10
Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.直接作用抗病毒药物的无干扰素慢性丙型肝炎治疗不会改变肝硬化患者新发肝细胞癌的短期风险。
Aliment Pharmacol Ther. 2018 Feb;47(4):516-525. doi: 10.1111/apt.14427. Epub 2017 Dec 4.
引用本文的文献
1
The Impact of Oncogenic Viruses on Cancer Development: A Narrative Review.致癌病毒对癌症发展的影响：一篇综述
Biology (Basel). 2025 Jul 1;14(7):797. doi: 10.3390/biology14070797.
2
Hepatocyte transformation is induced by laminin γ2 monomer.层粘连蛋白 γ2 单体诱导肝细胞转化。
Cancer Sci. 2024 Sep;115(9):2972-2984. doi: 10.1111/cas.16265. Epub 2024 Jul 1.
3
Meeting the challenges of hepatocellular carcinoma post sustained virologic response in the post-direct- acting antiviral era: A path forward: Editorial on "Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication".直面直接抗病毒药物时代持续病毒学应答后肝细胞癌的挑战：前进之路：关于“直接抗病毒药物时代未满足的需求：丙型肝炎病毒根除后肝细胞癌的风险及分子机制”的社论
Clin Mol Hepatol. 2024 Oct;30(4):677-681. doi: 10.3350/cmh.2024.0418. Epub 2024 Jun 11.
4
Serum MicroRNA profiles in chronic hepatitis C Egyptian patients before and after combined sofosbuvir and daclatasvir treatment.慢性丙型肝炎埃及患者在接受索非布韦和达卡他韦联合治疗前后的血清 microRNA 谱。
BMC Infect Dis. 2024 Jan 9;24(1):67. doi: 10.1186/s12879-023-08016-2.
5
Review of heart transplantation from hepatitis C-positive donors.丙型肝炎病毒阳性供体心脏移植的综述。
World J Transplant. 2022 Dec 18;12(12):394-404. doi: 10.5500/wjt.v12.i12.394.
6
Viral Hepatitis Among African Immigrants with Hepatocellular Carcinoma in Minnesota: High Prevalence Yet Low Awareness.明尼苏达州非洲移民肝细胞癌患者中的病毒性肝炎：高患病率但低知晓率。
J Immigr Minor Health. 2023 Apr;25(2):357-364. doi: 10.1007/s10903-022-01400-1. Epub 2022 Sep 15.
7
Immune-Related lncRNAs with WGCNA Identified the Function of SNHG10 in HBV-Related Hepatocellular Carcinoma.通过加权基因共表达网络分析（WGCNA）鉴定出与免疫相关的长链非编码RNA（lncRNA），明确了SNHG10在乙型肝炎病毒相关肝细胞癌中的功能。
J Oncol. 2022 Jul 6;2022:9332844. doi: 10.1155/2022/9332844. eCollection 2022.
8
Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature.阿托伐他汀可正向调节临床肝细胞癌风险基因特征。
Hepatol Commun. 2022 Sep;6(9):2581-2593. doi: 10.1002/hep4.1991. Epub 2022 Jun 16.
9
Human Papillomavirus Infection Is Associated with Decreased Risk of Hepatocellular Carcinoma in Chronic Hepatitis C Patients: Taiwan Nationwide Matched Cohort Study.人乳头瘤病毒感染与慢性丙型肝炎患者肝细胞癌风险降低相关：台湾全国匹配队列研究
Cancers (Basel). 2022 Mar 2;14(5):1289. doi: 10.3390/cancers14051289.
10
Liver Disease Outcomes after Sustained Virological Response in Patients with Chronic Hepatitis C Infection Treated with Generic Direct-Acting Antivirals.慢性丙型肝炎感染患者使用通用型直接抗病毒药物治疗后持续病毒学应答的肝病结局
Am J Trop Med Hyg. 2022 Feb 28;106(5):1522-33. doi: 10.4269/ajtmh.21-0918.
本文引用的文献
1
Hepatitis C Guidance 2019 Update: American Association for the Study of Liver Diseases-Infectious Diseases Society of America Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection.《2019年丙型肝炎指南更新：美国肝病研究协会-美国传染病学会关于丙型肝炎病毒感染检测、管理及治疗的建议》
Hepatology. 2020 Feb;71(2):686-721. doi: 10.1002/hep.31060.
2
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.在纳入监测项目的肝硬化患者中，直接抗病毒治疗 HCV 后肝细胞癌的发生率。
Gastroenterology. 2018 Nov;155(5):1436-1450.e6. doi: 10.1053/j.gastro.2018.07.015. Epub 2018 Jul 19.
3
Systematic review with meta-analysis: recurrence of hepatocellular carcinoma following direct-acting antiviral therapy.系统评价与荟萃分析：直接作用抗病毒治疗后肝细胞癌的复发。
Aliment Pharmacol Ther. 2018 Jul;48(2):127-137. doi: 10.1111/apt.14823. Epub 2018 May 30.
4
Does interferon-free direct-acting antiviral therapy for hepatitis C after curative treatment for hepatocellular carcinoma lead to unexpected recurrences of HCC? A multicenter study by the Japanese Red Cross Hospital Liver Study Group.根治性治疗肝细胞癌后无干扰素直接作用抗病毒治疗丙型肝炎是否会导致 HCC 意外复发？日本红十字会医院肝脏研究组的一项多中心研究。
PLoS One. 2018 Apr 16;13(4):e0194704. doi: 10.1371/journal.pone.0194704. eCollection 2018.
5
Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents.直接作用抗病毒药物治疗的丙型肝炎相关肝硬化患者肝细胞癌的发生率。
Gastroenterology. 2018 Aug;155(2):411-421.e4. doi: 10.1053/j.gastro.2018.04.008. Epub 2018 Apr 12.
6
Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.直接作用抗病毒药物治疗丙型肝炎病毒感染与肝癌发病风险：一项回顾性队列研究。
Aliment Pharmacol Ther. 2018 May;47(9):1278-1287. doi: 10.1111/apt.14593. Epub 2018 Mar 7.
7
Direct-acting antivirals do not increase the risk of hepatocellular carcinoma recurrence after local-regional therapy or liver transplant waitlist dropout.直接作用抗病毒药物不会增加局部区域治疗或肝移植候补名单退出后肝细胞癌复发的风险。
Hepatology. 2018 Aug;68(2):449-461. doi: 10.1002/hep.29855. Epub 2018 May 16.
8
The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals: An ERCHIVES study.直接作用抗病毒药物治疗丙型肝炎后肝细胞癌的短期发病率并未增加：一项 ERCHIVES 研究。
Hepatology. 2018 Jun;67(6):2244-2253. doi: 10.1002/hep.29707. Epub 2018 Apr 19.
9
The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: Role of the treatment regimen.丙型肝炎肝硬化患者持续病毒应答者发生肝细胞癌的风险：治疗方案的作用。
J Hepatol. 2018 Apr;68(4):646-654. doi: 10.1016/j.jhep.2017.10.033. Epub 2017 Nov 16.
10
Short-term risk of hepatocellular carcinoma after hepatitis C virus eradication following direct-acting anti-viral treatment.直接作用抗病毒治疗清除丙型肝炎病毒后肝细胞癌的短期风险。
Aliment Pharmacol Ther. 2018 Jan;47(1):104-113. doi: 10.1111/apt.14380. Epub 2017 Oct 16.
Zotero 插件